This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Survival, Epidemiology, and End Results | |
|---|---|
| Name | Survival, Epidemiology, and End Results |
| Specialty | Epidemiology, Biostatistics, Oncology |
Survival, Epidemiology, and End Results
Survival, epidemiology, and end results intersect fields that track population outcomes across time, drawing on methods used by figures and institutions such as Joseph Lister, Florence Nightingale, Centers for Disease Control and Prevention, World Health Organization, National Cancer Institute to quantify morbidity and mortality. Studies reference cohort designs from investigators like Richard Doll, Austin Bradford Hill, W. Edwards Deming and data registries maintained by entities including Surveillance, Epidemiology, and End Results (SEER), Framingham Heart Study, British Medical Journal, The Lancet to report prognosis and survival metrics.
Survival metrics are central to reporting by organizations such as National Institutes of Health, American Cancer Society, International Agency for Research on Cancer, European Medicines Agency, Food and Drug Administration, providing context for trials led by investigators like James Watson, Francis Crick, Rosalind Franklin, Craig Venter. Epidemiologic surveillance draws on registries from SEER Program, National Center for Health Statistics, Eurostat, Office for National Statistics and is interpreted using frameworks advanced by scholars such as John Snow, William Farr, Ignaz Semmelweis, Percival Pott.
Epidemiology of survival outcomes uses cohort and case-control approaches popularized by Richard Doll, Austin Bradford Hill, Alexander Fleming, Paul Ehrlich, integrating data from population sources including Framingham Heart Study, Nurses' Health Study, Million Women Study, UK Biobank, All of Us Research Program. Disease-specific survival reporting often references registries like SEER Program, Cancer Research UK, European Cancer Observatory, International Agency for Research on Cancer and policy documents from World Health Organization, Pan American Health Organization, Centers for Disease Control and Prevention. Outbreak- and chronic-disease surveillance intersects with methods from John Snow, William Farr, Joseph Bazalgette, Louis Pasteur in quantifying temporal trends, geographic distributions, and demographic differentials.
Survival analysis methods trace to statisticians and researchers such as Ronald Fisher, Jerzy Neyman, Egon Pearson, David Cox, Bradley Efron. Key techniques include Kaplan–Meier estimators used in trials run by groups like European Organisation for Research and Treatment of Cancer, Cox proportional hazards models applied in analyses by Framingham Heart Study, competing-risks frameworks used in reports from SEER Program, and parametric models referenced in reports by International Agency for Research on Cancer. Techniques are implemented in software projects and institutions including R (programming language), SAS Institute, StataCorp, Python (programming language), guided by guidelines from CONSORT, STROBE, PRISMA, and regulatory standards from Food and Drug Administration, European Medicines Agency.
End results reporting exemplified by SEER Program from the National Cancer Institute interacts with cancer registries like Cancer Research UK, Nordic Cancer Registries, Japanese Cancer Association, Australian Institute of Health and Welfare to produce survival tables, stage-specific outcomes, and population-based reports. Publications in outlets such as Journal of the American Medical Association, The Lancet Oncology, New England Journal of Medicine synthesize SEER-derived estimates alongside clinical trial data from cooperative groups including Children's Oncology Group, Gynecologic Oncology Group, SWOG. Outcome reporting standards draw on audit programs from Commission on Cancer, National Cancer Registration and Analysis Service, European Cancer Information System.
Determinants of survival and risk factors are characterized in studies by investigators and institutions including Richard Doll, Austin Bradford Hill, Framingham Heart Study, Nurses' Health Study, World Health Organization, Centers for Disease Control and Prevention. Sociodemographic gradients referenced in reports from United Nations, World Bank, Organisation for Economic Co-operation and Development interact with clinical determinants described by collaborative groups such as International Consortium for Health Outcomes Measurement, Global Burden of Disease Study, Institute of Health Metrics and Evaluation. Biological determinants involve pathways studied by laboratories associated with Harvard University, Johns Hopkins University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center.
Statistical measures include hazard ratios and confidence intervals used in meta-analyses published in Cochrane Collaboration, British Medical Journal, Journal of Clinical Oncology, with calibration and validation approaches from TRIPOD Statement, STARD, CONSORT guidance. Measures such as median survival, five-year survival, relative survival, cause-specific survival are estimated using methods implemented in packages from R (programming language), SAS Institute, StataCorp and interpreted in regulatory contexts overseen by Food and Drug Administration, European Medicines Agency, National Institute for Health and Care Excellence.
Public health implications of survival reporting inform policy decisions by World Health Organization, United Nations, Centers for Disease Control and Prevention, European Commission, United States Congress, and programmatic responses by Bill & Melinda Gates Foundation, Wellcome Trust, Robert Wood Johnson Foundation. Outcome data from SEER Program, Global Burden of Disease Study, Institute of Health Metrics and Evaluation underpin screening recommendations from United States Preventive Services Task Force, vaccination policies by Advisory Committee on Immunization Practices, and cancer control planning by International Agency for Research on Cancer, Union for International Cancer Control.